Evidence map›Paper›PMID 31636343›Full record

ArticleLeukemia2020

Enhanced expression of the sphingosine-1-phosphate-receptor-3 causes acute myelogenous leukemia in mice.

Samuel Vorbach, Albert Gründer, Fengbiao Zhou, Christoph Koellerer, Jonas S Jutzi, Manuela Simoni, Laura Riccetti, Peter J Valk, Mathijs A Sanders, Carsten Müller-Tidow and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Samuel Vorbach *Department of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.
Albert Gründer *Department of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.
Fengbiao ZhouDepartment of Medicine, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, 69120, Heidelberg, Germany.
Christoph KoellererDepartment of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.
Jonas S JutziDepartment of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.
Manuela SimoniDept. of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Via Giardini 1355, Modena, Italy.ORCID http://orcid.org/0000-0002-2133-4304
Laura RiccettiDept. of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Via Giardini 1355, Modena, Italy.
Peter J ValkDepartment of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Mathijs A SandersDepartment of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Carsten Müller-TidowDepartment of Medicine, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, 69120, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-7166-5232
Jerzy-Roch NoferInstitute of Clinical Chemistry and Laboratory Medicine, University Medical Center Hamburg-Eppendorf, 20251, Hamburg, Germany.
Heike L Pahl *Department of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany. Heike.Pahl@uniklinik-freiburg.de.
Francesco Potì *Dept. of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Via Giardini 1355, Modena, Italy.ORCID http://orcid.org/0000-0002-1708-0719

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute myeloid leukemia (AML) carries a 10-100 fold lower mutational burden than other neoplastic entities. Mechanistic explanations for why a low number of mutations suffice to induce leukemogenesis are therefore required. Here we demonstrate that transgenic overexpression of the wild type sphingosine-1-phosphate receptor 3 (S1P

Indexed as

Gene Expression Regulation, LeukemicAnimalsFingolimod HydrochlorideHematopoietic Stem CellsHumansLeukemia, Myeloid, AcuteMiceMice, Inbred C57BLMice, TransgenicMutationSignal TransductionSphingosine-1-Phosphate ReceptorsTranscriptomeTransgenesFingolimod HydrochlorideSphingosine-1-Phosphate Receptors

Identifiers

PMID31636343

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.